Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Condition(s):Breast CancerLast Updated:March 12, 2020Withdrawn
Hide Studies Not Open or Pending
Condition(s):Breast CancerLast Updated:March 12, 2020Withdrawn
Condition(s):Metastatic Renal Cell CarcinomaLast Updated:April 26, 2018Completed
Condition(s):Coronary Artery DiseaseLast Updated:February 9, 2018Unknown status
Condition(s):Neuroendocrine TumorsLast Updated:July 29, 2022Completed
Condition(s):Inoperable, Locally Advanced or Metastatic, ER-positive Breast CancerLast Updated:March 12, 2024Recruiting
Condition(s):Acute Coronary Syndrome; De Novo StenosisLast Updated:August 28, 2023Recruiting
Condition(s):Rejection Heart Transplant; ImmunosuppressionLast Updated:August 19, 2019Unknown status
Condition(s):Late Complication From Kidney TransplantLast Updated:July 13, 2022Completed
Condition(s):Kidney Transplant RejectionLast Updated:July 6, 2023Recruiting
Condition(s):Neuroendocrine Neoplasms (Tumours)Last Updated:November 9, 2020Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.